



To enrol your patients in the

TEVA-SUNITINIB PATIENT CARE PROGRAMSM,

please complete this form and return it to:

Fax: 1.833.377.0557 Phone: 1.877.445.6984

Email: info@SunitinibTevaCanada.com

PATIENT INFORMATION					
Last name:			First name:		
Patient health card:		Date of birt	: YYYY MM DD Gender: OM OF Other		I ○ F ○ Other
Address:		'	City:		Province:
Postal code: Mobile phone number:			Alternate phone number:		Ok to leave VM: Yes No
Preferred time to call: \(\int A.M.\) P.M. Email		Email:			
Preferred method of contact: O Phone Email Text			Preferred language: O English O French Other:		
Drug insurance coverage/plan:	Private OPublic OUnknow	n O Drug plan	paperwork submitted to payer-	—Date submitted	d: YYYY MM DD
PATIENT CONSENT					
	and which is attached hereto. I e	expressly consent			ccordance with its privacy policy, which on outside Canada, including within the
Written consent Date: YYYY MM		M DD	O Verbal consent		Date: YYYY MM DD
X Patient signature:			X HCP signature:		
PRESCRIPTION R _x			PRESCRIBER INFORMATION		
Teva-Sunitinib is available as 12.5 mg 25 mg and 50 mg capsules.			Prescriber consent (not required if enroled at the pharmacy)		
Sunitinib () 50 mg or () mg PO once daily for 4 weeks followed by 2 weeks rest.			I authorize Teva-Sunitinib Patient Care Program SM to be my designated agent to forward this prescription by fax or other mode of delivery to the pharmacy chosen by the above-named patient. This prescription represents the original prescription drug		
Quantity: doses Refills:			order for the patient. Any prior	r Sunitinib prescri	iption for this patient is being cancelled
Other instructions:				itinib, in accordar	nsmitted. I confirm that this patient nce with the Product Monograph and as described herein.
Sunitinib 37.5 mg or	mg PO once daily continuousl	.y.	Last name:	F	irst name:
Quantity: doses Refills:		Licence number:	V	Vork phone:	
Other instructions:			Office fax:		
			Office email:		
			Address/clinic stamp:		
To enrol your patients in the TEVA-SUN follow these instructions:	IITINIB PATIENT CARE PROGRAM	1 sm ,			
 Download and save the form to you Complete the form fields and sign. Save the form. 	r desktop.				
Fax completed form to 1.833.377.0557 email info@SunitinibTevaCanada.com	or				
Teva-Sunitinib is indicated for:			X Prescriber Signature		
the treatment of gastrointestinal strong	nal tumour (GIST) after failure of in	matinib	A escriber signature		Date: YYYY MM DD

Consult the product monograph for important information on contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use at TevaCanada.com; or by calling 1.800.268.4127 ext. 3; or by email druginfo@tevacanada.com.

 $\boldsymbol{\cdot}$ the treatment of metastatic renal cell carcinoma (MRCC) of clear cell histology. • the treatment of patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET), whose

disease is progressive.

To enrol your patients in the

TEVA-SUNITINIB PATIENT CARE PROGRAMSM,

please complete this form and return it to:

Fax: 1.833.377.0557 Phone: 1.877.445.6984 Email: info@SunitinibTevaCanada.com

PRIVACY POLICY FOR THE TEVA-SUNITINIB PATIENT CARE PROGRAMSM TEVA SUPPORT SOLUTIONS® (TSS)

Teva Support Solutions (TSS) respects your privacy and is strongly committed to protecting your personal information. This privacy policy explains the information we may collect and how we use and safeguard that information. If you have any questions, or if you would like more information about the manner in which we or our authorized service providers treat your personal information, or to access your personal information in our records, do not hesitate to contact us using the information provided below.

Why we ask you for personal information

In order for Teva Support Solutions to offer you the services you require, we may request that you provide us with your personal information, including personal health information, or we may obtain personal information from your referring physician, pharmacist, insurance company, public payer or any other healthcare professional or payer that may possess the requisite information. We will not access, collect, use, or disclose any of your personal information unless you have provided your consent. We will only ask for the personal information necessary to serve you, to comply with our pharmacovigilance commitments and obligations (which may apply even after you leave the TSS Patient Support Program), and to research, develop, and improve our products and services. Some of the services provided by TSS include:

- · providing you with personalized services to meet your specific needs;
- · determining the suitability of our services for your needs;
- · determining your eligibility for our products and services;
- · determining eligibility for reimbursement assistance;
- · providing you with information about our products and services.

Access and use of information

The personal information you provide will be accessed and used only by TSS, our affiliates and authorized agents, and respective staff members, who are required to maintain the confidentiality of your personal information. By agreeing to provide your information in accordance with the terms of this privacy policy, you are giving your consent for us to disclose relevant information from your file to your referring physician, as well as to our affiliates and authorized third parties who assist us in providing services to you (i.e., only the information required for the execution of the service being required from the third party). Such third parties may include, but are not limited to:

- our healthcare professionals (for providing appointment reminders, coordinating appointments, offering advice about or follow-ups on your therapy);
- · our service providers (for therapy coverage);
- our mailing house (responsible for sending printed information and publications); or
- · potential payers or reimbursement organizations.

You consent to be contacted by TSS via phone, text or email and to the transfer of personal information by phone, fax or email between TSS, your insurer, and your healthcare provider(s) for the purpose of determining your eligibility for TSS and the delivery of TSS services. Email and text may be used during the course of your participation in TSS to inform you about your status in the TSS program, provide TSS services, and to provide notifications and reminders. You acknowledge that neither email nor text are secure methods of communication. Information in emails and texts has the potential to be accessed and read by a third party. Electronic communication is at your option and you may withdraw this option to communicate electronically at any time.

We may share information with external firms, which would be engaged by us to conduct pharmaceutical market research on our behalf, and which may contact you for the sole purpose of gathering market research information. We may also share information with affiliates and health authorities that collect certain information for the purposes of safety monitoring of marketed products, including information, if applicable, relating to the pregnancy of patients enroled in the TSS Patient Support Program.

Furthermore, your information may also be shared with others if explicitly authorized or required by applicable law. Any information which we might have shared with such third parties will be held on a confidential basis and will only be kept by them for as long as it is reasonably needed for the intended purpose of the services they are providing, after which the data in their possession will be securely destroyed.

At no time and under no circumstance will your information be sold to any third party for any reason. The data contained in your file will only be kept for as long as it is reasonably needed, and it will only be used for the purpose stated in your file. Once the purpose has been achieved, your file will be deleted unless you require further services, or unless we are required to maintain a copy under applicable law. You may choose to withdraw your consent to our access, collection, use, or disclosure

You may choose to withdraw your consent to our access, collection, use, or disclosure of some or all personal information at any time. However, please understand that your decision may prevent us from providing you with services and information that you request.

Protection

Your information will be stored on a confidential basis at the TSS offices and/or secure locations both inside and outside of Canada, including within the European Union, Israel or the USA. It is a condition of receiving services from TSS that you expressly consent to the secure storage of your personal information outside Canada. It is protected by various physical, technical and administrative security measures such as magnetic locks, data encryption, and a system of individual usernames and passwords for each staff member.

Contact on behalf of another person

Teva Support Solutions must deal directly and exclusively with you; therefore, it is not possible for others to contact TSS on your behalf. If you would like a family member, friend, or anyone else to receive services from us, please give him/her our phone number.

Keeping your information accurate

We are committed to keeping your personal information accurate as long as we need it for the purposes previously described. You play an important role in helping us achieve this goal. You may update your information by contacting us either by phone or email. Your prompt notification of any contact information changes will assist us in providing you with the requested services.

Changes to the privacy policy

TSS reserves the right to change, modify, or amend this policy at any time. However, when a significant change has been made, you will be notified within a reasonable time either by phone, mail, or email.

Teva Support Solutions® Privacy Officer (Generics)

30 Novopharm Court, Toronto, Ontario M1B 2K9, Canada PrivacyOfficerCanada@tevacanada.com

TEVA, and the design version thereof, are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under licence.

The Teva-Sunitinib Patient Care ProgramSM is a service mark of Teva Pharmaceutical Industries Ltd. and is used under licence.

The Teva-Sunitinib Patient Care ProgramSM is managed by the services provided through Teva Support Solutions (TSS) $^{\circ}$.